Portfolio company
Maro Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This biotechnology firm develops non-genotoxic conditioning agents for patients undergoing hematopoietic stem cell transplants and gene therapies.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
HI-Bio
This biotechnology company develops targeted therapies for patients suffering from severe immune-mediated diseases.
Appia Bio
This company develops engineered allogeneic cell therapies from hematopoietic stem cells for cancer patients.
MoglingBio
The company develops pharmacological therapies that inhibit Cdc42 protein activity to rejuvenate aged stem cells for patients with blood disorders and immune dysfunction.
Orca Bio
This company develops high-precision allogeneic cell therapies to treat patients with blood cancers and autoimmune diseases by replacing diseased immune systems with donor cells.
Clade Therapeutics
This biotechnology company develops stem cell-derived medicines to treat patients with cancer and autoimmune diseases.
Marea Therapeutics
This biotechnology company develops medicines for cardiometabolic and cardioendocrine diseases using human genetic data for patients with unmet medical needs.
Mariposa Therapeutics
This biotechnology company develops a topical small-molecule therapy for patients with the rare genetic skin condition epidermolysis bullosa simplex.
Claris Bio
This biotechnology company develops topical therapies for patients with orphan ophthalmic disorders and corneal diseases including limbal stem cell deficiency.